• / Free eNewsletters & Magazine
  • / My Account
Home>Search Results

Related Content

  1. Videos
  2. Articles
  1. Generic Biologics Face Uphill Battle

    Morningstar generic-pharmaceuticals analyst Brian Laegeler discusses the outlook for generic biologics in the U.S. given a strong branded-drug lobby and complex manufacturing processes.

  2. Will 'Knockout' Mice Make a Knockout Stock?

    After a strong runup from our recommendation, is it time to take money off the table in Lexicon Pharmaceuticals?

  3. Going Global to Ease Drug Trial Process

    Contract research organization Parexel is exploiting its global footprint to rapidly enroll patients in drug studies.

  4. Will a Medco/Express Scripts Merger Pass Regulatory Muster?

    Shareholders would be well-served by the pharmacy benefit managers' merger, but regulators are unlikely to sign off on it, says Morningstar's Matt Coffina.

  1. Jazz Pharmaceuticals, Inc. JAZZ Q4 2011 Earnings Call Transcript

    Good day ladies and gentlemen and welcome to Jazz Pharmaceuticals Full Year and Fourth Quarter 2011 Financial Results Conference Call. Following an introduction from the Company, we will open the call to questions.

Multiple Pages
ShareEmail
Print
Text Size
Comment
blog comments powered by Disqus
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.